Bristol Myers' (BMY) Krazati sNDA for CRC Gets Priority Review

Bristol Myers (BMY) announced that the FDA has accepted its supplemental new drug application (sNDA) for Krazati (adagrasib) in combination with Erbitux (cetuximab) to treat patients with previously treated KRASG12C-mutated locally advanced or metastatic (la/m) colorectal cancer (CRC). The FDA has assigned the Priority Review status to the company’s sNDA for the combination therapy.A filing designated as a Priority Review reduces the review period by four months. A final decision from the regulatory body is ...